Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
United Airlines Flight Hits Light Pole During Newark Landing, FAA Investigates 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
Middle East Conflict Impacts Australia and New Zealand Businesses 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Apple Q2 2026 Earnings Surge as iPhone 17 Sales Drive Record Revenue 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
Berkshire Hathaway Q1 Earnings Jump 18% as Greg Abel Signals Disciplined Growth Strategy 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
Coles Group Q3 Sales Rise Driven by Supermarkets and E-Commerce Growth 
GameStop Proposes $56 Billion eBay Acquisition in Bold Strategic Move 
Anthropic’s $1.5B AI Venture with Wall Street Firms Targets Private Equity Market 
Spirit Airlines Shuts Down Flights, Issues Refunds After Financial Collapse 
NEW YORK, May 04, 2018 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the District of Utah on behalf of investors who purchased Myriad Genetics, Inc. ("Myriad") (NASDAQ:MYGN) securities between August 13, 2014 and March 12, 2018.
Click here to learn about the case: http://www.wongesq.com/pslra-c/myriad-genetics-inc?wire=3. There is no cost or obligation to you.
According to the complaint, throughout the Class Period, the Company issued materially false and misleading statements and/or failed to disclose that: (i) Myriad was submitting false or otherwise improper claims for payment under Medicare and Medicaid for the Company’s hereditary cancer testing; (ii) the foregoing conduct would foreseeably subject Myriad to heightened regulatory scrutiny and/or enforcement action; (iii) Myriad’s revenues from its hereditary cancer testing were in part the product of improper conduct and unlikely to be sustainable; and (iv) as a result, Myriad’s public statements were materially false and misleading at all relevant times. On March 12, 2018, Myriad Genetics filed an 8-K with the United States Securities and Exchange Commission disclosing the receipt of a subpoena from the Department of Health and Human Services concerning “an investigation into possible false or otherwise improper claims submitted for payment under Medicare and Medicaid.”
If you suffered a loss in Myriad you have until June 19, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-c/myriad-genetics-inc?wire=3.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]
